---
title: "Inferior turbinate IgG4-rich lymphoid hyperplasia mimicking IgG4-related disease"
id: "frontiers-in-immunology-11-localized-lymphoid-hyperplasia-with-prominent-igg4-positive-plasma-cells-in-the"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-localized-lymphoid-hyperplasia-with-prominent-igg4-positive-plasma-cells-in-the"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1898657"
published_at: "2026-10-14T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Inferior turbinate IgG4-rich lymphoid hyperplasia mimicking IgG4-related disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-localized-lymphoid-hyperplasia-with-prominent-igg4-positive-plasma-cells-in-the
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1898657)
- **Published At:** 2026-10-14T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- A retrospective review identified 41 patients (0.3% of 14,103 endoscopies) with focal submucosal inferior turbinate masses observed between January 2020 and May 2023. - Mean age was 51.5 years; there was a male predominance (75.6%). Median symptom duration was prolonged at 36 months. Allergic history was present in 36.6% of patients. - Biopsies were obtained from 18 lesions showing mucosal disruption (crusting or bleeding); all 18 exhibited dense lymphoplasmacytic infiltration on histology. - Immunohistochemistry demonstrated variable but often substantial numbers of **IgG4**-positive plasma cells; 10 of 18 biopsies (55.6%) exceeded an IgG4+/IgG+ ratio of 40%. - Characteristic histologic hallmarks of systemic **IgG4-related disease**—storiform fibrosis and obliterative phlebitis—were absent in all biopsies. Lymphoid follicle formation occurred in 8 of 18 biopsies. - Application of the 2019 ACR/EULAR classification criteria classified only two patients as IgG4-RD; both had extra-nasal disease. Using the 2011 comprehensive criteria on the 18 biopsied cases yielded 2 definite, 7 probable, and 9 possible IgG4-RD classifications. - Management approaches varied: 10 patients underwent surgery, 4 received corticosteroids, 4 received both, and 23 were observed. Surgery produced durable symptom control in 9 of 10 patients (90%). Corticosteroid response was inconsistent (2 of 4 improved). Observation led to spontaneous improvement in 5 of 23 (21.7%); most remained stable without progression. - Investigators concluded these focal, **IgG4**-rich lymphoid lesions of the anterior inferior turbinate may represent a distinct benign inflammatory entity rather than sinonasal manifestation of systemic IgG4-RD. The source calls for further study to define pathophysiology, optimal management, and long-term outcomes.
## Clinical Analysis & Structured Key Points
Frontiers | Localized lymphoid hyperplasia with prominent IgG4-positive plasma cells in the inferior turbinate mimicking IgG4-related disease ORIGINAL RESEARCH article Front. Immunol. , 14 October 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1898657 Published in Frontiers in Immunology Autoimmune Disorders 7 impact factor 11.3 citescore Editor & Reviewers Edited by V O Valentyn Oksenych Reviewed by S H Seokchan Hong F F Fatemeh Farrokh Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Baseline characteristics of study participants. View in article Table 2 Histological findings of nasal biopsy. View in article Table 3 Baseline characteristics of study participants by treatment. View in article Table 4 Summary of treatment and outcomes in 41 patients with localized lymphoid hyperplasia. View in article ORIGINAL RESEARCH article Front. Immunol. , 14 October 2026 Sec. Autoimmune Disorders Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1898657 Localized lymphoid hyperplasia with prominent IgG4-positive plasma cells in the inferior turbinate mimicking IgG4-related disease D H Doo Hee Han 1 J I Ji In Jung 2 J Y Ju Yeon Kim 3 J K Jiwon Koh 4 J W Jun Won Park 2 E B Eun Bong Lee 2 J K Jin Kyun Park 2 * 1. Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea 2. Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea 3. Division of Rheumatology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong-si, Republic of Korea 4. Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea See more Article metrics View details Abstract Objectives: Localized lymphoid masses of the inferior turbinate with prominent IgG4-positive plasma cell infiltration are occasionally encountered in clinical practice, yet their nature and relationship to IgG4-related disease (IgG4-RD) remain uncertain. This study aimed to characterize the clinical, histopathological, and therapeutic features of these lesions. Methods: We retrospectively reviewed patients presenting with localized submucosal masses of the inferior turbinate identified on nasal endoscopy at Seoul National University Hospital between January 2020 and May 2023. Biopsies were performed in cases with mucosal disruption, including crusting or bleeding. Classification of IgG4-RD was based on the 2019 American College of Rheumatology/European League Against Rheumatism criteria. The 2011 Comprehensive diagnosis criteria were applied to the patients with available biopsies. Results: Of 14,103 patients undergoing nasal endoscopy, 41 (0.3%) demonstrated localized inferior turbinate submucosal lesions. Eighteen patients underwent biopsy, all of which revealed dense lymphoplasmacytic infiltration with variable IgG4-positive plasma cell counts. An IgG4+/IgG+ plasma cell ratio exceeding 40% was observed in 10 cases (55.6%). However, characteristic histopathological features of IgG4-RD, including storiform fibrosis and obliterative phlebitis, were absent. Only two patients fulfilled the 2019 classification criteria for IgG4-RD, both of whom had extra-nasal involvement. According to the 2011 Comprehensive diagnosis criteria, 2 patients were classified as definite IgG4-RD. Spontaneous improvement during observation occurred in a minority of patients. Surgical treatment resulted in durable symptom control with minimal recurrence, whereas corticosteroid therapy showed variable effectiveness. Conclusions: Localized IgG4-rich lymphoid hyperplasia of the inferior turbinate may represent a distinct benign inflammatory lesion, mimicking a sinonasal manifestation of IgG4-RD. Further studies are required to clarify its pathophysiology, optimal management, and long-term outcomes. 1 Introduction IgG4-related disease (IgG4-RD) is a rare, multi-system fibro-inflammatory condition characterized by dense lymphoplasmacytic infiltration, storiform fibrosis, obliterative phlebitis, tissue infiltration by IgG4-positive plasma cells, and frequently elevated serum IgG4 concentrations ( 1 – 3 ). In the head and neck region, IgG4-RD most commonly affects the lacrimal, orbital, parotid, and submandibular glands, as well as the thyroid gland and cervical lymph nodes. In contrast, sinonasal involvement is uncommon ( 4 ). When present, sinonasal IgG4-RD typically manifests with nasal obstruction, chronic rhinosinusitis, or epistaxis ( 5 , 6 ) and rarely presents as hypertrophy or sclerosis of the inferior turbinate ( 7 ). Localized masses of the inferior turbinate may cause nasal symptoms but differ from diffuse turbinate hypertrophy. These lesions are typically focal, confined to the anterior portion of the inferior turbinate, and may occur independently of rhinitis or sinusitis. Histopathological examination often demonstrates dense lymphoplasmacytic infiltration with IgG4-positive plasma cells, mimicking the features of IgG4-RD ( 6 ). However, it remains unclear whether these lesions represent a localized nasal manifestation of systemic IgG4-RD or a distinct, previously unclassified inflammatory disease entity. Distinguishing IgG4-RD from benign lymphoid hyperplasia has important clinical implications. IgG4-RD generally requires prolonged systemic glucocorticoid therapy, which carries substantial risks including diabetes, osteoporosis, cardiovascular disease, and cataracts ( 8 – 10 ). In contrast, benign lymphoid lesions may be managed conservatively or treated surgically if symptomatic. This study aimed to characterize the clinical, histopathological, and therapeutic features of localized lymphoid masses of the inferior turbinate and to clarify their relationship to IgG4-RD. 2 Methods 2.1 Study design and patients This retrospective cohort study included patients who underwent nasal endoscopic evaluation for various nasal symptoms at Seoul National University Hospital between January 2020 and May 2023. Biopsies were performed when inferior turbinate masses demonstrated mucosal disruption, including crusting or bleeding. Patients subsequently underwent systemic evaluation for autoimmune or inflammatory disease ( Figure 1 ). Patients were treated at the discretion of the primary physician. Figure 1 Overview of patient flow. The study was conducted in accordance with the revised Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2212-139-1389). Informed consent was waived due to the retrospective study design. 2.2 Endoscopic examination All patients underwent standard nasal endoscopic examination conducted by a rhinologist (HDH) using 3 mm 0-degree rigid endoscopes (Karl Storz, Tuttlingen, Germany) in an outpatient clinic setting. 2.3 Histopathological evaluation and immunohistochemistry Biopsy specimens obtained during endoscopy were fixed in 10% neutral buffered formalin for 24–72 hours, processed, and subsequently embedded into paraffin blocks. From these paraffin blocks, 4-μm sections were cut for hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC). The immunohistochemistry analysis was performed using anti-IgG rabbit polyclonal antibody (A0423; Dako, Glostrup, Denmark) and anti-IgG4 mouse monoclonal antibody (clone MRQ-44; Ventana Medical Systems, Tucson, AZ, USA) with the BenchMark XT System (Ventana Medical System), following the manufacturer’s instructions. Tonsil tissue was used as a positive control. 2.4 Evaluation of IgG4-RD All subjects underwent a comprehensive medical assessment, encompassing evaluations of skin, joint, and soft tissue involvement. Laboratory analysis included erythrocyte sedimentation rate (ESR), and high-sensitivity C-reactive protein (hs-CRP). Autoantibodies such as rheumatoid factor (RF), antinuclear antibody (ANA), and serum IgG4 levels were examined in cases where an autoimmune disease was clinically suspected. IgG4-RD was diagnosed according to the 2019 American College of Rheumatology/European League Against Rheumatism classification criteria (ACR/EULAR) of IgG4-RD ( 11 ). Histologic IgG4-RD was defined by the presence of two or more of the following three features: dense lymphocytic infiltrates, storiform fibrosis, and phlebitis. Immunohistochemical IgG4-RD was defined by the presence of over 10 IgG4+ cells per high power field (HPF) and the IgG4/IgG ratio exceeding 0.4 ( 3 ). In patients with available biopsy specimens, the 2011 comprehensive diagnostic criteria for IgG4-RD were also applied ( 12 ). These criteria integrate characteristic organ swelling or mass-forming lesions, serum IgG4 levels, and histopathologic findings to categorize patients as having definite, probable, possible, or no IgG4-RD. 2.5 Statistical analysis Continuous variables were presented as means ± standard deviations or medians with interquartile ranges (IQR), as appropriate. Categorical variables were expressed as absolute counts and percentages. Group comparisons were performed using the Student’s t -test or Mann–Whitney U test for comparisons between two groups and one-way ANOVA or the Kruskal-Wallis test for comparisons among three or more groups, as appropriate. Categorical variables were compared using the chi-square test or Fisher’s exact test, as appropriate. Statistical significance was defined at p < 0.05. R-Studio was utilized for all analyses. 3 Results 3.1 Patient characteristics Among the 14,103 patients evaluated for nasal symptoms between January 2020 and May 2023 at the ENT clinic of the Seoul National University Hospital, 41 (0.3%) patients exhibited a submucosal lymphoid hyperplasia in the inferior turbinate during rhinoscopy ( Figure 1 ). Thirty-seven patients had isolated nasal disease, while four exhibited extra-nasal involvement. Biopsies were performed on 16 out of the 37 patients with isolated nasal lesions and two out of the four patients with extra-nasal involvement, all of whom exhibited features of mucosal damage, including crusting and bleeding. The mean age of the 41 patients was 51.5 ± 16.4 years, with a male predominance (75.6%). The median symptom duration was 36.0 [4.1- 105.0] months. Rhinorrhea was the most common symptom, observed in 31.7% of patients, followed by nasal obstruction (29.3%) and nasal mass (12.2%). Notably, 15 (36.6%) of 41 patients reported allergies. Patients with extra-nasal symptoms had higher total IgG and IgG4 levels than those with isolated nasal lesions ( Table 1 ). Table 1 Characteristics Isolated nasal lesions (N = 37) Extra-nasal involvement (n = 4) P Value Age, years 51.9 ± 15.7 47.8 ± 25.2 0.634 Sex, male 29 (78.4) 2 (50.0) 0.520 Duration, months 27.2 [3.1 - 83.2] 105.3 [47.3 - 183.8] 0.195 Nasal symptoms NA NA NA Rhinorrhea 13 (35.1) 0 (0) 0.385 Nasal obstruction 10 (27.0) 2 (50.0) 0.703 Nasal mass 5 (13.5) 0 (0) 1.000 Sneezing 5 (13.5) 0 (0) 1.000 Postnasal drip 3 (8.1) 0 (0) 1.000 Nasal pain 3 (8.1) 0 (0) 1.000 Crusting 6 (16.2) 0 (0) 0.899 Nasal bleeding 2 (5.4) 0 (0) 1.000 Allergy 11 (29.7) 4 (100) 0.026 Laboratory tests WBC, x 10 3 /mm 3 5730.0 [4865.0 - 6910.0] 9500.0 [6660.0 - 10870.0] 0.087 Eosinophil, 10 3 /mm 3 2.5 [1.9 - 4.0] 2.7 [1.6 - 4.2] 0.957 Hemoglobin, g/dL 13.3 ± 1.2 14.0 ± 0.8 0.229 Platelet, 1000/mm 3 230.0 [216.0 - 265.5] 275.0 [248.5 - 291.5] 0.137 ESR, mm/hr 12.0 [7.0 - 20.0] 13.5 [8.0 - 19.5] 0.953 CRP, mg/dL 0.1 [0.0 - 0.2] 0.1 [0.1 - 0.2] 1.000 Serum IgG, mg/dL 1251.5 ± 122.7 1838.0 ± 275.8 0.038 Serum IgG4, mg/dL 55.2 ± 48.4 206.9 ± 111.8 0.024 Baseline characteristics of study participants. Data are presented as the mean ± standard deviation, median [IQR] or number (%). Numbers in bold indicate a statistical significance. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WBC, White blood cells. 3.2 Endoscopic findings Rhinoscopy revealed yellowish sessile submucosal masses with intact overlying mucosa in the anterior portion of the inferior turbinate ( Figures 2A–C ). In 18 patients, the overlying mucosa showed signs of hemorrhage and crusting, and these lesions were biopsied. Figure 2 Representative endoscopic findings of lymphoid nasal mass. Rhinoscopy reveals sessile submucosal masses with intact overlying mucosa in the anterior portion of the inferior turbinate. Representative images of a mild (A) , moderate (B) and a severe case with bloody crust (C) were depicted. (D) The lesion was surgically removed. (E) The lesion did not recur three months after surgical resection. 3.3 Histologic characteristics All 18 biopsies exhibited dense lymphoplasmacytic infiltrates. Lymphoid follicle formation was identified in eight (44.4%) cases. Fibrosis was observed in 10 (55.6%) cases but none of them exhibited storiform fibrosis. Obliterative phlebitis was absent ( Table 2 ). Immunohistochemical analysis revealed the substantial presence of CD3-positive T cells and CD20-positive B cells within the infiltrates, along with a significant amount of IgG and IgG4 positive cells. Ki-67 expression co-localized with CD20-positive B cells ( Figure 3 ). Furthermore, all samples demonstrated varying amounts of IgG4-expressing plasma cells with ten (55.6%) cases exhibiting the IgG4+/IgG+ ratio exceeding 40%, thereby meeting the criteria for the immunohistologic diagnosis of IgG4-RD ( Table 2 ). Table 2 Biopsy finding Total (n = 18) Lymphoid follicle 8 (44.4%) Fibrosis 10 (55.6%) Storiform fibrosis 0 (0) Phlebitis 0 (0) IgG, cells/HPF 353.0 ± 230.1 IgG4, cells/HPF 80.0 [40.0 - 102.0] IgG4/IgG ratio, % 40.0 [9.6 - 48.0] immunohistochemical diagnosis of IgG4-RD 10 (55.6%) Histological findings of nasal biopsy. Data are presented as the mean ± standard deviation, median [IQR] or number (%). HPF, high power field; Ig, immunoglobulin; IgG4-RD, IgG4-related disease. Figure 3 Histopathological examination of nasal masses. Hematoxylin and eosin (H&E) staining revealed a dense lymphoplasmacytic infiltrate, forming a prominent lymphoid structure. Abundant CD3-positive T cells and CD20-positive B cells were observed, along with substantial IgG and IgG4 production. Notably, more than 100 IgG4-positive plasma cells were present per high-power field, with an IgG4/IgG plasma cell ratio exceeding 40%. 3.4 Diagnosis according to the 2019 ACR/EULAR classification criteria and the 2011 comprehensive diagnosis criteria All patients met the entry criteria based on the lymphoid mass, while none met the exclusion criteria of the 2019 ACR/EULAR classification criteria for IgG4-related disease. Among the 41 patients, only two were classified as having IgG4-RD according to the 2019 ACR/EULAR classification criteria. Both patients had extra-nasal involvements. The first case, a 27-year-old man, displayed a constellation of chronic pansinusitis, pancreatitis, and parotid enlargement. With a serum IgG4 level of 164.7 mg/dL (normal upper limit: 157 mg/dL), his total IgG4-RD score was 33. The second patient was a 76-year-old man who presented with pansinusitis, lacrimal gland engagement, pituitary gland lesion, and periaortic infiltrate. His serum IgG4 level was 68.2 mg/dL, and the IgG4-EULAR/ACR score was 28. Nasal biopsies from two IgG4-RD patients displayed numerous IgG-positive cells. However, lymphoid follicle formation, storiform fibrosis, and phlebitis were absent in both patients. The 2011 Comprehensive diagnosis criteria were applied to the 18 patients with available biopsies. Of these, 9, 7, and 2 patients were classified as possible, probable, and definite IgG4-RD, respectively. 3.5 Treatment and outcome Patients were treated at the discretion of their physicians. Of 41 patients, 18 (43.9%) patients experiencing substantial nasal symptoms were treated; 10 underwent surgery, 4 received corticosteroid therapy, and 4 received both. Clinical and laboratory characteristics were generally comparable across treatment groups, except for the prevalence of crusting ( Table 3 ). Surgical resection demonstrated a high success rate, achieving no recurrence in 9 (90%) of 10 patients whereas corticosteroid therapy was less effective, with only 2 (50%) of 4 patients showing a response ( Table 4 ). Among the 4 patients who received both surgery and corticosteroid, only 2 (50%) patients improved. In contrast, 23 patients were managed with observation alone. During the follow-up, spontaneous improvement occurred in 5 patients (21.7%), whereas the remaining 18 (78.3%) had persistent but stable lesions without clinical progression during follow-up. None of the patients managed conservatively subsequently required surgical intervention or systemic corticosteroid therapy. Table 3 Characteristics Observation (n=23) CS (n=4) Surgery (n=10) CS + Surgery (n=4) P Value Age, years 54.0 ± 15.6 53.8 ± 20.8 47.5 ± 18.3 45.0 ± 15.0 0.622 Sex, male 19 (82.6%) 2 (50.0%) 7 (70.0%) 3 (75.0%) 0.531 Duration, months 59.6 ± 71.0 116.7 ± 99.1 50.7 ± 77.8 99.6 ± 174.1 0.524 Follow-up, months 51.1 ± 7.1 52.5 ± 6.6 50.3 ± 7.2 62.5 ± 4.5 0.027 Nasal symptoms Rhinorrhea 11 (47.8%) 0 (0.0%) 2 (20.0%) 0 (0.0%) 0.069 Nasal obstruction 7 (30.4%) 1 (25.0%) 3 (30.0%) 1 (25.0%) 0.993 Nasal mass 1 (4.3%) 1 (25.0%) 1 (10.0%) 2 (50.0%) 0.062 Sneezing 5 (21.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.216 Postnasal drip 3 (13.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.469 Nasal pain 1 (4.3%) 0 (0.0%) 2 (20.0%) 0 (0.0%) 0.347 Crusting 1 (4.3%) 1 (25.0%) 1 (10.0%) 3 (75.0%) 0.003 Nasal bleeding 2 (8.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.649 Allergy 9 (39.1%) 3 (75.0%) 1 (10.0%) 2 (50.0%) 0.113 Laboratory tests WBC, x 10 3 /mm 3 6440.6 ± 3103.4 8627.5 ± 3109.5 5652.0 ± 1395.8 5825.0 ± 1078.6 0.280 Eosinophil, 10 3 /mm 3 2.8 ± 2.0 3.4 ± 2.1 3.5 ± 2.2 3.1 ± 0.7 0.858 Hemoglobin, g/dL 13.1 ± 1.2 13.3 ± 2.0 13.6 ± 1.1 13.7 ± 0.8 0.640 Platelet, 1000/mm 3 236.8 ± 50.9 257.2 ± 28.0 249.3 ± 56.8 256.0 ± 39.9 0.805 ESR, mm/hr 11.6 ± 6.7 26.2 ± 19.2 13.0 ± 9.0 16.0 ± 10.9 0.102 CRP, mg/dL 0.2 ± 0.3 0.2 ± 0.1 0.4 ± 0.6 0.1 ± 0.1 0.743 Serum IgG, mg/dL 1360.0 1626.3 ± 415.3 1270.5 ± 127.9 1193.3 ± 145.3 0.161 Serum IgG4, mg/dL NA 138.7 ± 114.3 71.5 ± 57.6 99.1 ± 138.6 0.605 Baseline characteristics of study participants by treatment. Data are presented as the mean ± standard deviation. Numbers in bold indicate a statistical significance. NA, not applicable; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CS, corticosteroid; WBC, White blood cells. Table 4 Treatment group Improved CS only (n = 4) 2 (50.0) Surgery only (n = 10) 9 (90) Surgery + CS (n =4) 2 (50.0) Observation (n = 23) 5 (21.7) Summary of treatment and outcomes in 41 patients with localized lymphoid hyperplasia. Data are presented as number (%). CS, corticosteroids. The two patients with IgG4-RD received only medical treatment. The 27-year-old patient with IgG4-RD responded well to corticosteroids and immunosuppressants, including rituximab. In the case of the 76-year-old patient with IgG4-RD, extra-nasal lesions responded to corticosteroids, while the nasal symptoms such as sinusitis did not respond. 4 Discussion In this study, lymphoid masses located in the anterior portion of the inferior turbinate demonstrated dense lymphoplasmacytic infiltration with IgG4-producing cells, immunohistochemically resembling IgG4-related disease (IgG4-RD). Although lymphoid follicle formation was frequently observed, neither storiform fibrosis nor obliterative phlebitis was identified in these lesions. None of the patients fulfilled the 2019 ACR/EULAR classification criteria for IgG4-RD unless concomitant extra-nasal IgG4-RD involvement was present. Clinically, nasal symptoms improved following surgical resection but showed limited responsiveness to corticosteroid therapy. Collectively, these findings suggest that these nasal lymphoid lesions might represent a distinct benign chronic inflammatory disease entity rather
## Related Clinical Research

- [Understanding Vaccine Skepticism: Insights from Two Decades of Parental Conversations](https://medichelpline.com/clinical-feed/stat-news-1-she-s-spent-two-decades-talking-to-parents-who-don-t-vaccinate-their-children.md)
- [WHO director-general race: five candidates and questions about the U.S. role](https://medichelpline.com/clinical-feed/stat-news-1-at-least-five-candidates-vie-to-become-the-next-who-leader-as-questions-over-u.md)
- [Public Acceptability of Self-Payment for Community Pharmacists' Services — National Survey Results](https://medichelpline.com/clinical-feed/medrxiv-29-public-acceptability-of-self-payment-for-community-pharmacists-services-a.md)
- [Vitamin B5 derivative linked to reduced psoriasis plaques and inflammation in small trial](https://medichelpline.com/clinical-feed/medical-news-today-0-vitamin-b5-derivative-may-reduce-psoriasis-plaques-and-inflammation-small-trial.md)
- [GLP-1 Agonist Use Associated with Faster Bowel Recovery After Lumbar Fusion](https://medichelpline.com/clinical-feed/pubmed-41400023.md) (DOI: 10.1097/BRS.0000000000005598)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.